IJCP Editorial Team
Study Finds Comparable Outcomes for Acetaminophen and COX Inhibitors in PDA Treatment
A new retrospective analysis has assessed whether acetaminophen, increasingly used for patent ductus arteriosus (PDA) closure, poses added risks to extremely preterm infants. With concerns rising about its potential impact on lung health, researchers compared outcomes between infants treated with acetaminophen and those receiving only cyclooxygenase (COX) inhibitors.
Among 1,921 infants studied, 32.6% received acetaminophen and 67.3% received COX inhibitors alone. Multidrug therapy (42.9% vs 4.7%) and surgical or catheter-based PDA closure (26.5% vs 19.9%) were more common in the acetaminophen group. Rates of death or moderate-to-severe bronchopulmonary dysplasia at 36 weeks’ postmenstrual age were similar between both groups (57.1% vs 58.3%).
Although acetaminophen was linked to slightly higher predischarge mortality (13.3% vs 10.0%) after adjusting for early clinical factors, this association was not significant after accounting for later postnatal variables.
Researchers conclude that acetaminophen does not increase the combined risk of death or BPD in extremely preterm infants, though the mortality signal highlights the need for further investigation.
Source: Jensen EA, DeMauro SB, Rysavy MA, et al. Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary Morbidity. 2024;154(2).
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Related FAQs
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article